Focus Fund
  • Home
  • About
    • Mission & Values
    • Investment Strategy
  • Team
  • Portfolio
  • News
  • Contact
Select Page

KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR’s Lead Anti-CD47 Candidate in Blood Cancers

by rpadmin | May 26, 2021 | Kahr, PR Newswire

Focus Fund and MD Anderson Launch Investment Fund to Support Promising Investigational Cancer Therapies in Early-Stage Clinical Trials

by rpadmin | Oct 20, 2020 | PR Newswire

Sources

  • BioSpace
  • Kahr
  • Mereo BioPharma
  • PR Newswire

At The Focus Fund, we invest in promising technologies that are close to being tested in humans. Our objective is to leverage MD Anderson resources to provide investors with superior risk-adjusted returns.

At the Cancer Focus Fund, we invest in promising therapies in late preclinical development through Phase I and Phase Ib/II clinical trials. Our objective is to provide support to accelerate the development of these therapeutics together with the clinical trials expertise and infrastructure of MD Anderson.

Texas Medical Center

2450 Holcombe Boulevard
Houston, TX 77021

Shreveport

2031 Kings Highway
Shreveport, LA 71103

Pages

  • Home
  • About
  • News
  • Portfolio
  • Contact
  • Team

Copyright © 2022 Focus Fund|Developed by RP Agency